Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    0.025 (2.04%)
Bid:
1.20
Ask:
1.35
Spread: 0.15 (12.50%)
Market Cap: £20.07m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Update on CFO Appointment

29 Nov 2016 07:00

RNS Number : 3503Q
Genedrive PLC
29 November 2016
 

 

 

For release: 29 November 2016

 

genedrive plc ("genedrive" or the "Company")

 

Update on CFO Appointment

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that, following his appointment as Chief Financial Officer and a Director of the Company as announced on 21 September 2016, Matthew Fowler will join genedrive plc on 13 December 2016.

 

Matthew joins genedrive plc with over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive plc, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes.

 

Before joining Scapa Group plc, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.

- Ends -

 

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

 

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGGGUGUPQGMR
Date   Source Headline
1st Jun 20267:00 amRNSBlock Listing Returns
26th May 20267:00 amRNSBoard Changes
6th May 202611:56 amRNSHolding(s) in Company
5th May 20267:00 amRNSSussex NHS Trust transitions MT-RNR1 test to BAU
21st Apr 20267:00 amRNSNHS England commercial strategy for MT-RNR1
20th Apr 20267:00 amRNS-RInteractive Investor Hub Updates
16th Apr 20267:00 amRNSCYP2C19 kit implemented in North Bristol NHS Trust
30th Mar 20267:00 amRNSInterim Results to 31 December 2025
12th Mar 20269:52 amRNSHolding(s) in Company
12th Mar 20267:00 amRNSHolding(s) in Company
12th Mar 20267:00 amRNSHolding(s) in Company
11th Mar 20263:22 pmRNSHolding(s) in Company
11th Mar 20263:22 pmRNSHolding(s) in Company
9th Mar 202611:29 amRNSResult of General Meeting
9th Mar 20267:00 amRNSResult of Open Offer and Additional Subscriptions
24th Feb 20262:32 pmRNSHolding(s) in Company
24th Feb 202612:05 pmRNSHolding(s) in Company
19th Feb 20267:00 amRNSPublication of circular, notice of GM & timetable
13th Feb 20264:22 pmRNSCompletion of Placing
13th Feb 20262:04 pmRNSProposed Direct Subscription to raise up to £3.5m
6th Feb 20269:50 amRNSHolding(s) in Company
3rd Feb 202610:59 amRNSHolding(s) in Company
27th Jan 20262:18 pmRNSHolding(s) in Company
19th Jan 20263:01 pmRNSProposed equity raise of up to £6.0 million
31st Dec 202511:44 amRNSResult of AGM
31st Dec 202511:44 amRNSResult of AGM
18th Dec 20257:00 amRNSScotland NHS “test of change” pilot programme
11th Dec 20259:00 amRNSNew interactive investor hub
9th Dec 20253:45 pmRNSAgreement of Shareholder Loan
8th Dec 20254:00 pmRNSAnnual Report and Accounts and date of AGM
5th Dec 20257:00 amRNSFinal Results
3rd Dec 20257:00 amRNSNotice of Results
1st Dec 20253:19 pmRNSBlock Listing Returns
1st Dec 20257:00 amRNSResults presented re. NHS CYP2C19 Genotype Testing
27th Nov 202510:09 amRNSNHS implementation guide published for CYP2C19
26th Nov 20257:00 amRNSScotland national roll-out of MT-RNR1 ID Kit
19th Nov 20257:00 amRNSFurther re Shareholder Loan
4th Nov 20257:00 amRNSMT-RNR1 ID Kit in Dublin’s Rotunda Hospital
31st Oct 20257:00 amRNSPotential Shareholder Loan
29th Oct 20254:35 pmRNSHolding(s) in Company
28th Oct 20257:00 amRNSMOU with Kingdom of Saudi Arabia for MT-RNR1 ID
24th Oct 20254:30 pmRNSApplication for Listing & Total Voting Rights
15th Oct 202510:49 amRNSResult of General Meeting
10th Oct 20251:32 pmRNSHolding(s) in Company
10th Oct 20251:31 pmRNSHolding(s) in Company
10th Oct 20259:00 amRNSHolding(s) in Company
9th Oct 202510:23 amRNSFurther re Equity Financing
6th Oct 20257:00 amRNSFurther re Equity Financing
2nd Oct 20256:18 pmRNSHolding(s) in Company
1st Oct 202512:31 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.